Company
AndzonBio1
Targeting core disease mechanisms to address underserved CVRM conditions
- Status
- Operatingas of 2026-09-21
- Business model
- B2B
- Headquarters
- Paris, France
- Legal name
- AndzonBio1
Claim, correct or request removal
Record updated 28 September 2026
About
AndzonBio1 is a multi-asset biotech company developing a pipeline of first-in-class therapeutics for the transformative treatment of Hypertrophic CardioMyopathy (HCM), Liver Fibrosis and post Myocardial Infarction Fibrosis
Funding snapshot
- Total raised
- $3.3MSum of rounds, as of 2026-09-21Source (opens in a new tab)
- Latest round
- Seed, $3.3M2024-10-29
Funding rounds
- Seed
- $3.3M2024-10-29, Company stated
Loading relationship preview